Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines

Brian Schuler


Migraines are the third most prevalent disease in the world affecting approximately 15% of the population, or over one billion people. Each year, employers lose greater than $13 billion due to 113 million missed work days due to migraine. A great cost-burden and high incidence rate show a continued need for migraine treatment options. In choosing a treatment for a migraine attack, quick onset of action is one of the most important qualities. Common choices include the triptan class, NSAIDs, and a combination of aspirin, caffeine, and acetaminophen. In addition, there has been increased research into calcitonin gene-related peptides (CGRP). Due to side effect profiles, the monoclonal antibodies have been more successful than the antagonists studied. Monoclonal antibodies alone, though, have not completely eradicated migraine days per month and more research is needed.

Full Text:



  • There are currently no refbacks.

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.